waverley pharma inc said monday that it is evaluating strategies for a number of its generic drugs as the company faces increased market pressures in the us and europe the canadian specialty pharmaceutical company said it has had to cut the prices of its generic drugs to attract more business in the face of steep competition and rising costs which have led to price erosion and thinning margins waverley pharma currently has four generic products approved for sale in the uk and two generic products pemetrexed and bortezomib approved for sale in other parts of the us and europe at the same time waverley pharma said it is committing more resources to its parp1 inhibitor program to attract a development partner or a buyer for the anticancer agents lead compound after the program showed positive early results